Metformin use and the risk of anal intraepithelial neoplasia in type II diabetic patients

Aim Emerging evidence has suggested that metformin may be protective against the development of human‐papillomavirus‐related cancers. Anal intraepithelial neoplasia (AIN) is highly associated with human papillomavirus infection and a precancerous status of anal cancer. The aim of this study was to i...

Full description

Saved in:
Bibliographic Details
Published in:Colorectal disease 2021-12, Vol.23 (12), p.3220-3226
Main Authors: Hsu, Angela Ting‐Wei, Hung, Ya‐Ching, Fang, Sandy H., D’Adamo, Christopher R., Mavanur, Arun A., Svoboda, Shane M., Wolf, Joshua H.
Format: Article
Language:English
Subjects:
AIN
anal dysplasia
Anus Neoplasms - epidemiology
Anus Neoplasms - etiology
Carcinoma in Situ - drug therapy
Carcinoma in Situ - epidemiology
Case-Control Studies
Diabetes
diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Diagnosis
HIV
Human immunodeficiency virus
Human papillomavirus
Humans
Metformin
Metformin - therapeutic use
Papillomavirus Infections - complications
Papillomavirus Infections - epidemiology
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Emerging evidence has suggested that metformin may be protective against the development of human‐papillomavirus‐related cancers. Anal intraepithelial neoplasia (AIN) is highly associated with human papillomavirus infection and a precancerous status of anal cancer. The aim of this study was to investigate the relationship between metformin usage and the development of AIN in a large national sample. Methodology The IBM MarketScan dataset was used to design a nested case–control study from 2010 to 2017. Patients aged 18–65 years with type 2 diabetes mellitus (DM) were evaluated, and cases of AIN were identified. Four controls were randomly selected in the risk set of each case by using incidence density sampling. The association between metformin usage and AIN was assessed using multivariate logistic regression modelling. Results A total of 258 patients with type 2 DM were diagnosed with AIN during the study interval, and these were matched to 1032 control patients without a diagnosis of AIN. Patients who developed AIN had 38% lower odds of prior metformin use compared to those without a history of AIN (P 
ISSN:1462-8910
1463-1318
DOI:10.1111/codi.15860